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Abstract: Genetic markers can be used in seeds and in plants to distinguish drug-type from fiber-type
Cannabis Sativa L. varieties even at early stages, including pre-germination when cannabinoids are
not accumulated yet. With this aim, this paper reports sequencing results for tetrahydrocannabinolic
acid synthase (THCAS) and cannabidiolic acid synthase (CBDAS) genes from 21 C. sativa L. varieties.
Taking into account that THCAS- and CBDAS-derived enzymes compete for the same substrate, the
novelty of this work relies in the identification of markers based on both THCAS and CBDAS rather than
THCAS alone. Notably, in our panel, we achieved an adequate degree of discrimination (AUC 100%)
between drug-type and fiber-type cannabis samples. Our sequencing approach allowed identifying
multiple genetic markers (single-nucleotide polymorphisms—SNPs—and a deletion/insertion) that
effectively discriminate between the two subgroups of cannabis, namely fiber type vs. drug type. We
identified four functional SNPs that are likely to induce decreased THCAS activity in the fiber-type
cannabis plants. We also report the finding on a deletion in the CBDAS gene sequence that produces
a truncated protein, possibly resulting in loss of function of the enzyme in the drug-type varieties.
Chemical analyses for the actual concentration of cannabinoids confirmed the identification of
drug-type rather than fiber-type genotypes. Genetic markers permit an early identification process
for forensic applications while simplifying the procedures related to detection of therapeutic or
industrial hemp.
Keywords: SNPs; markers; Cannabis; THCAS; CBDAS; drug
1. Introduction
Cannabis sativa L. (commonly called cannabis) is an herbaceous plant belonging to the Cannabis
genus of the Cannabaceae family. The Cannabis genus includes morphologically variable varieties that
can be mainly divided in two categories: Drug-type, suitable for recreational/therapeutic purposes,
and fiber-type used in industrial and agronomy field. The different purposes of the cannabis genotypes
depend on the ability of each variety or accession to synthesize and accumulate secondary metabolites
known as cannabinoids. Cannabinoids represent a group of more than 100 natural products [1,2], of
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which tetrahydrocannabinol (THC) is the main (psycho) active compound. Tetrahydrocannabinolic acid
(THCA) and cannabidiolic acid (CBDA) are formed from the same precursor, namely cannabigerolic
acid (CBGA). The THCA synthase (THCAS) and CBDA synthase (CBDAS) are necessary to produce
the metabolites THCA and CBDA [3–8].
The biosynthetic process leads to a carboxylated cannabinoid form. When cannabis inflorescences
are subjected to intense heat, such as when they are smoked, cannabinoids are gradually decarboxylated
to THC and cannabidiol (CBD) [9]. Thus, the phenotypic features, including the different types and
contents of cannabinoids in the plant, can significantly vary among C. sativa varieties. It is known
that some C. sativa L. plants lack the ability to form cannabinoids [10]. This is generally due to a
knockout factor that inhibits the metabolic pathway upstream of THCAS. In these plants, neither
CBD nor THC can be produced due to the absence of such upstream precursors in the biosynthetic
pathway [11,12]. The sequences of THCA synthase (THCAS) and CBDA synthase (CBDAS) genes
were previously characterized [6,13]. The sequence of the CBDAS gene has been shown to be very
similar to that of the THCAS gene (87.9% similarity) [14]. Literature has also reported that with four
single-nucleotide polymorphisms (SNPs) on THCAS gene, it was possible to differentiate some varieties
of drug-type and non-drug cannabis plants [15]. The two cannabis types were discriminated by Kojoma
and collaborators [10] studying 13 different varieties and using specific DNA polymorphisms.
Staginnus and colleagues [16] distinguished three qualitative chemotypes (chemical phenotypes)
depending on the CBD/THC ratio and suggested that they differed because of polymorphisms in
the THCAS sequence. De Meijer and colleagues [17] identified a locus (B) with two co-dominant
alleles (BT and BD). The homozygous BT/BT genotype underlies the THC-predominant phenotype,
and BD/BD underlies the CBD-predominant phenotype. The intermediate phenotype is induced
by the heterozygous genotype (BT/BD). Additionally, Staginnus [16] evidenced that the qualitative
chemotype was subjected to Mendelian inheritance, while the absolute quantity of THC and CBD was
a quantitative trait (quantitative chemotype).
Van Bakel and colleagues [18] and, more recently, Weiblen and colleagues [19] suggested a model
to explain the segregation of THCA and CBDA among marijuana and hemp cultivars. This model
consists of a linked multi-locus model of inheritance in which a functional THCAS gene is associated
with two non-functional CBDAS homologous genes in marijuana, and a functional CBDAS gene is
linked to three non-functional THCAS homologous genes in hemp.
Considering that most of the previous activity was related to a relatively limited number of
genotypes and considering that in such works only THCAS was considered, novel approaches suitable
as diagnostic tests for seeds and plants are advisable. On these bases, the scope of our study was to
discover highly reliable markers able to effectively discriminate fiber-type (hemp) from drug-type
(marijuana) cannabis seeds and plants. We therefore considered 167 cannabis samples (both fiber-type
and drug-type varieties, and both plants and seeds of the identified varieties). Seeds from each variety
were grown to also include the chemical profiles of the plants at maturity related to their genotypes.
Our objects considered sequencing both the THCAS and CBDAS genes (following the design of specific
primers) and predicting the related proteins.
2. Materials and Methods
2.1. Experimental Cultivations and Chemical Analyses: Fiber-Type Cannabis
Ten different fiber-type (hemp) varieties of cannabis (Table S1) were chosen from among a collection
of hemp at the Institute of Agronomy, DIPROVES, Università Cattolica del Sacro Cuore, Piacenza,
Italy. Seeds were sown and plants were grown in an experimental field in Piacenza (North of Italy).
Fifty fiber-type plants were analyzed in total (five of each variety). Inflorescences were obtained at
the plant maturity stage, dried in an oven at 40 ◦C for 48 h, and then prepared for chemical analysis,
performed according to Appendino and collaborators. [20] The samples were crushed, cleaned of seeds
and secondary stems, and finely milled with a spice grinder. Next, a sub-sample (75 mg) was extracted
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in 15 mL methanol (reagent grade, Sigma-Aldrich, St. Louis, MO, USA) for 1 h at 50 ◦C in an ultrasonic
bath and centrifuged at 6000× g for 5 min. Subsequently, an aliquot of the extract was evaporated in an
oven at 50 ◦C for 2 h and then maintained at 120 ◦C for 2 h to achieve total cannabinoid decarboxylation.
The samples were dissolved in the initial volume of methanol and analyzed using an in-house method
based on liquid chromatography coupled to triple quadrupole tandem mass spectrometry (LC-MS/MS)
via an electrospray ionization source [21]. An Agilent 1200 series liquid chromatograph and an Agilent
6410A mass spectrometer were used for this analysis. Reverse-phase chromatographic separation was
achieved on a CORTECS C18 analytical column (2.7 µm, 150 mm × 3 mm inner diameter) equipped
with a guard column (Waters, Milford, MA, USA) and using a binary mobile phase system (solvent A:
Milli-Q water with 0.1% HCOOH; and solvent B: Methanol with 0.1% HCOOH). The gradient was
increased from 75% B to 90% B in 16 min, the flow rate was 0.18 mL/min, and the column temperature
was 45 ◦C. Cannabinoid (THC and CBD) analysis was performed under multiple reaction monitoring
and positive ionization mode.
The electrospray conditions were as follows: A capillary voltage of 4000 V, vaporizer temperature
of 300 ◦C, nitrogen flow rate of 8 L/min (18 psi), and nitrogen temperature of 300 ◦C. Each analyte
was acquired using at least two tandem MS transitions, and the daughter ion ratio was used for
confirmatory purposes, thereby achieving the required analytical specificity. Reference standards
for each cannabinoid, with concentrations ranging from 0.1 to 200 mg/kg in methanol, were used as
external standards for calibration and quantification purposes.
2.2. Experimental Cultivations and Chemical Analyses: Drug-Type Cannabis
Eleven different drug-type varieties (Table S1) were selected as suitable for indoor experimental
cultivation by examining characteristic plant features such as feminization, auto-flowering, height,
flowering period and THC content so that a variety of different phenotypic features were included in
the examined pool of samples. For the drug-type varieties, seeds were purchased on the Internet from
different online cannabis shops. Seeds purchased online were sown indoors, with one plant per pot.
A total of 47 plants reached the maturity stage under controlled environmental conditions. All the
experiments were performed under governmental authorizations.
Chemical analyses were performed on inflorescences and upper leaves of dried plants after
indoor cultivation. Approximately 100–150 mg of each homogenized sample were solubilized in
chloroform containing cholestane as an internal standard. The samples were examined by a gas
chromatography-flame ionization detector (GC-FID), using a 7820A Agilent GC to identify THC and
CBD and determine their percentages using a standardized analytical method. The column used
was an Agilent HP-5 fused silica capillary column with a length of 30 m, an inner diameter of 0.320
mm, and a film thickness of 0.25 µm (Agilent Technologies, Santa Clara, CA, USA). The carrier gas
(N2) flow rate was kept constant at 1 mL/min. One microliter of each sample was injected into the
GC-FID using a 5:1 split injection ratio. The injector temperature was 290 ◦C. The column oven was
programmed with an initial temperature of 200 ◦C for 0.5 min, followed by an increase to 260 ◦C at
a rate of 15 ◦C/min, and then the temperature was maintained at 260 ◦C for 4 min. For the purpose
of this study, the percentage values of the following cannabinoids were considered: THC, the main
compound of drug-type varieties that has psychoactive effects, and CBD, the main compound of
fiber-type varieties that has the same molecular precursor (CBG) as THC.
2.3. Isolation and Sequencing of DNA
Genetic analyses were performed on fresh leaves of each fiber-type and drug-type variety from
indoor cultivation and on seeds from each subgroup. A total of 50 fiber-type and 47 drug-type plants
from the experimental cultivations, as well as 50 seeds of the fiber-type varieties and 20 seeds of
the drug-type varieties, were directly processed for DNA extraction, amplification and sequencing.
In detail, the full-length coding sequence of THCAS was determined using both external and internal
primers previously reported in the literature (marked by an asterisk in Table S2) [10]. The primers for
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CBDAS were designed using Primer 3plus (www.bioinformatics.nl/cgi-bin/primer3plus) to be highly
specific for this gene (avoiding amplification of THCAS) and with the aim of gene amplification in
both fiber-type and drug-type cannabis. Two primers for each gene (THCAS and CBDAS) were used
to generate the full-length gene fragments, while the other primers served as internal primers in the
sequencing reactions (as indicated in Table S2). A BLASTn search against GenBank (www.ncbi.gov),
the specific cannabis database Comparative Genomics platform CoGe (http://genomevolution.org),
and the Cannabis Genome Browser (http://genome.ccbr.utoronto.ca/) was performed for each primer.
Only primers with 100% similarity to the corresponding gene were used in the following analysis.
Extraction of DNA from fresh leaves was performed using a DNeasy Plant Mini Kit (Qiagen,
Hilden, Germany) following the manufacturer’s protocol; however, the protocol was adapted for the
seeds (half volumes of reagents were used), which were first peeled and fragmented using a pestle and
mortar. The isolated DNA was loaded in a 1% agarose gel and compared with a reference DNA sample.
The amount of extracted DNA was approximately 10 ng/µL, and the quality was good for analyses
of both seeds and leaves. The amplification reaction, conducted using a Qiagen Multiplex PCR Kit,
was performed in a final volume of 25 µL using 10 µM primers and 5 ng of DNA. Amplification was
performed with an Applied Biosystems (Foster City, CA, USA) GeneAmp PCR System 9700, and the
PCR conditions were as follows: Preheating at 95 ◦C for 15 min followed by 30 cycles at 94 ◦C for 30 s,
57 ◦C for 90 s, and 72 ◦C for 90 s, and a final extension at 72◦ C for 10 min. The amplified products
were loaded on a 2% agarose gel in 1X TBE. After being stained with ethidium bromide, the amplified
products were photographed under UV light (254 nm). The products were then purified using Spin
MSB PCRapace (Stratec Molecular, Berlin, Germany). Sequencing was conducted using a BigDye
Terminator v3.1 Cycle Sequencing Kit (Life Technologies, Carlsbad, CA, USA) as follows: 4 µL reaction
mix, 3.2 pmol of primer, and 2 µL of the purified PCR product in 15 µL total volume. The sequences
were purified with a BigDye XTerminator Purification Kit and analyzed with an ABI PRISM 3130
Genetic Analyzer (Applied Biosystems).
2.4. Data Analysis
The sequences obtained were edited and aligned against the following reference sequences:
GenBank ID KJ469374 (fiber-type CBDAS-cultivar Carmen) and KJ469378 (drug-type THCAS) from
Weiblen et al. (2015). For each sample, a consensus sequence was produced by aligning all the
sequences obtained, including the reverse and forward strands, to cover the entire region of the gene.
The consensus sequence was generated with the SeaView platform [22]. The sequences have been
submitted to GenBank with the accession numbers from MG996399 to MG996439.
The sequences were aligned and compared with previously reported THCAS and CBDAS
sequences [10,13,19,23,24]. The sequences used in THCAS alignment were as follows: AB212836,
AB212829, AB212837, and AB212830 [10], and AB057805 [13]. In addition, those used in CBDAS
alignment were as follows: AB292682 [24], KP970864 and KP970857, and KJ469375 [19]. All sequences
were aligned using the MUSCLE algorithm [25], a tool of MEGA6 software [26]. The SNPs were
numbered according to the THCAS coding sequence of the drug-type cultivar Skunk (KJ469378) and
the CBDAS coding sequence of the fiber-type cultivar Carmen (KJ469374). The translated protein of
drug-type and fiber-type sequences of both THCAS and CBDAS were analyzed with PROVEAN [27]
to predict whether the protein sequence variation affected protein function.
The fas files containing the DNA sequences were converted to the comma-separated values (csv)
format using Fasta2excel online tool (http://users-birc.au.dk/biopv), and the resulting csv files were
imported into R version 3.0.2. The selection of important loci was performed as follows: Each locus was
treated as a categorical random variable and was used to predict the phenotype by univariate Firth’s [28]
penalized-likelihood logistic regression. The resulting p-values were adjusted for multiplicity by
Benjamini and Hochberg correction [29], which has been shown to be appropriate for use in this context
of dependence of p-values by Farcomeni [30,31]. The list of significant loci generated after adjustment
was used to generate a score, with 1 point assigned if the locus coincided with that of the consensus
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sequence for drug accessions, −1 point assigned if the locus coincided with that of the consensus
sequence for fiber accessions, and 0 points assigned otherwise. We proceeded by comparing optimal
scores based on one, two, or three up to the total number of significant loci. The optimal scores were
obtained by weighting the loci to maximize the area under the receiver operating characteristics curve
(AUC), under the constraint that most of the k weights were non-negative [32]. The parameter k varied
from 1 to the total number of loci and differed for deletions and SNPs. Furthermore, multidimensional
scaling based on Gower distances [33] was performed after grouping varieties into four groups based
on THC/CBD ratio (THC/CBD up to 0.05, THC/CBD from 0.05 to 0.2, THC/CBD from 0.2 to 10, and
THC/CBD more than 10).
3. Results
Chemical and genetic analyses for two experimental cultivations of cannabis plants and genetic
analyses for two pools of cannabis seeds revealed significant differences among the two varieties
(fiber-type and drug-type). Chemical and genetic analyses were performed on a total of 97 plants: 47
selected among 11 different drug-type varieties and 50 selected among 10 different hemp varieties,
based on the heterogeneity on CBD and/or THC content (see Figure 1). Genetic analyses only were
performed on a total of 70 seeds: 20 drug-type and 50 fiber-type from the same varieties (Table S1).
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Figure 1. Cannabidiol (CBD) and tetrahydrocannabinol (THC) content found in drug-type and hemp
varieties selected for the experimen .
3.1. Chemical Analysis
R sults of chemical analyses performed on mature plants from experimental cultivation showed
that the percentage of cannabinoids of the two subgroups of Cannabis was in agreement with the
previously published data [10,23]. In particular, all drug-type plants showed THC concentration from
2.08% to 11.80% of dry weight, and all fiber-type plants had less than 0.31% THC. The percentage
values of tetrahydrocannabinol (THC) and cannabidiol (CBD) were directly quantified using their
reference standard, and the THC/CBD ratio was then calculated (Table 1).
3.2. Multidimensional Scaling
he sequences of all cannabis samples were different from each other. I ord r to assess
within-variety v riation, we h ve grouped v ri ti s into four groups according to THC/CBD ratio
(Table S3). The overall variation as assessed by average mean entropy is 0.19. The average within-group
variation is 0.16, 0.07, 0.12, and 0.20 for groups 1, 2, 3, and 4, respectively. The between-group
variation is 0.11. We obtained biplot based on multidimensional scaling of Gower distances after this
grouping (Figure 2). It can be seen that (i) samples are non-completely overlapping, indicating that
each sample has a unique DNA sequence and that (ii) fiber-type and cannabis-type samples are almost
perfectly separated.
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Table 1. The main cannabinoid contents of the plants from the experimental cultivations collected
at the mature stage. The values are expressed as a percentage of inflorescence dry weight.
* SD = standars deviation.
NAME No. ofPlants CBD SD* THC SD* THC/CBD Group
Santhica 27 5 0.00 - 0.00 - 0.0 Fiber
Carmagnola 5 3.89 0.49 0.24 0.04 0.06 Fiber
Uso 31 5 0.24 0.13 0.03 0.02 0.12 Fiber
Ermes 5 2.53 0.37 0.15 0.03 0.06 Fiber
Finola 5 1.66 0.34 0.31 0.1 0.18 Fiber
Ermo 5 0.01 0.01 0.00 - 0.0 Fiber
Futura 75 5 3.18 0.21 0.18 0.02 0.05 Fiber
C.S. 5 3.91 0.36 0.24 0.02 0.08 Fiber
Tygra 5 1.97 0.38 0.31 0.12 0.18 Fiber
Carmaleonte 5 2.68 0.47 0.15 0.03 0.05 Fiber
60 Days Wonder 3 0.22 0.19 6.97 3.64 32.17 Drug
BC God Bud 11 0.20 0.08 6.40 3.89 32.00 Drug
Chocolate Kush 4 0.96 0.77 5.42 2.75 5.67 Drug
Chocolope 3 0.44 0.02 5.65 1.06 12.84 Drug
Flash Babylon 2 0.14 0.18 7.20 0.30 51.43 Drug
Golden Berry 2 0.42 0.35 11.80 4.30 28.10 Drug
Northern Light 4 1.81 1.84 6.40 4.90 3.53 Drug
Shiatsu Kush 8 0.40 0.19 6.10 3.39 15.44 Drug
Skunk #11 4 2.15 1.34 2.08 0.77 0.97 Drug
Star Ryder 4 0.84 1.04 11.33 3.28 13.53 Drug
UK Werkle 2 1.54 1.79 6.70 4.70 4.36 Drug
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3.3. Discovery of Highly Predictive Markers
The comparison of sequences allowed us to identify highly reliable markers of plant type. We
sequenced both the THCAS and the CBDAS genes and selected the most discriminating SNP loci
(highest predictive values) from among those determined to be statistically significant, including 47
SNPs in THCAS and 40 in CBDAS. We found that some SNPs were heterozygous in drug-type samples.
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We decided to focus on homozygous SNPs because they are most confident and reliable for our work
and future diagnostic analyses. Considering previously described four diagnostic SNPs in THCA
synthase gene [15], we found that three of them (pos953, pos1035 and pos1079) were heterozygous in
some drug-type samples.
Scores based on homozygous SNPs in the THCAS gene had an AUC of 100% for any of the following
25 loci: “pos136”, “pos137”, “pos154”, “pos221”, “pos269”, “pos287”, “pos300”, “pos355”, “pos383”,
“pos385”, “pos409”, “pos412”, “pos418”, “pos424”, “pos494”, “pos505”, “pos612”, “pos678”, “pos699”,
“pos744”, “pos749”, “pos763”, “pos862”, “pos864”, and “pos869”. Scores based on homozygous SNPs
in the CBDAS gene were also evaluated and were found to have an AUC of 100% for any of the
following eight loci: “pos407”, “pos545”, “pos583”, “pos588”, “pos613”, “pos637”, “pos688”, and
“pos704”. Of these SNP-based scores, only one locus among the 33 selected loci (Figure 3A, B) was
sufficient for discriminating between the two subgroups.
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Figure 3. Significant single-nucleotide polymorphisms (SNPs) able to discriminate between the two
cannabis subgroups of th different varieties (drug-type vs. fi er-type) are shown. Twenty-five
sig ificant SNPs are highlighted for THCAS (A) and eight for CBDAS (B). E ch base chang and ts
corresponding position (pos) in the gene are indic te .
Furthermore, we selected other statistically significant markers, particularly the deletion/insertion
polymorp is identified in CBDAS, using the sequence from a fiber-type variety (Carmen KJ469374)
as the reference sequence. Specifically, we detected a deletion of four bases from positions 153–156 and
an insertion of three bases at position 755 (AAC) in the drug-type varieties.
A score based on the deletio /insertion polymorphism of CBDAS was calc lated by ssigning
1.1 points to the deletion chosen at position 154 (drug-type varieties) and −1 point to the insertion
at position 755 + 3 (drug-type varieties). The possible values of the score were thus −1, 0, 0.1, a d
1.1. The AUC was 99.87% (95% CI: 99.65–100.00%) in this case, and the threshold of 0 (score > 0,
indicating cl ssification as a drug-type variety) s owed 100% sensitivity (95% CI: 100.00–100.00%)
and 95.56% specificity (95% CI: 88.37–100.00%). Therefore, the CBDAS deletion/insertion was also
abl to discriminate between the two cannabis subgroups (we also fou d a deletion/inserti n in the
THCAS gene that as discarded because the AUC score was 75%). The us of Be jamini a d Hochberg
corr ction [29] guarantee that th expected proportion of falsely detected mutations was below 5%.
The empirical res lts confirmed t at all sel cted SNPs were highl iscriminating between marijuana
and hemp. Sensitivity and specificity w r above 95% for several thresholds. Sensitivity analysis
revealed that these outst ing results were not dependent n the scoring system us d. The AUCs for
thes g netic mark rs reached 100% even whe only the CBDAS d leti n pol morphism was tested
toget r with one of the 33 SNPs listed above. Any score based on mutations that erfectly separated
the two subgroups of ca nabis achieved an AUC of 100% and p ssibly 100% sensitivity and specificity.
Our suggested scores also took into ccount the mutatio prevalence in our empirical data to maximize
Plants 2019, 8, 496 8 of 12
positive and negative predicted values. The mutations most reliably separating the two subgroups
were in positions 269, 494, 749, and 763 on THCAS; in positions 637 and 583 (A/T polymorphism) on
CBDAS; and a CBDAS deletion of four bases in positions 153–156 (CGTA) in drug-type genotypes
(a very early stop codon resulting in a truncated protein).
3.4. Predicted Protein Sequence of THCAS and CBDAS
To test the functional meaning of the significant mutations, two artificial genes were constructed:
A THCAS gene (containing the 25 selected SNPs of Figure 3A) and a CBDAS gene (containing eight
SNPs plus the insertion/deletion; Figure 3B). Both genes were translated using standard genetic
code from the MEGA6 platform. Polymorphisms in the primary structure of the protein were then
investigated (Figure 4), and the effect of amino acid substitutions assessed according to the expected
impact on secondary and tertiary structures and the mutation effect on the biological function of
the protein.
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(A) and cannabidiolic acid synthase (CBDAS) (B) causing amino acid ha ges in the primary structure of
the protein of fiber-type and drug-type genotypes. The di gram shows the amino acid changes involving
neutral (black box) and deleterious (red box) mutations of the protein sorted from PROVEAN an lysi .
With this aim, the chemical nature of the amino acids’ side chains was taken into account: changes
from hydrophobic to charged structures (and vice versa) were considered of high impact, while changes
from hydrophobic to polar, or from rigid/ring to fluid stru tures, w re co idered of moderate impact.
The mutated THCAS gene gave a protein with 18 amino a id changes caused by 19 n n-synonymous
mutations. A expected, most of the SNPs were functional with a high non-synonymous/synonymous
ratio (3.2), and 10 out of he 18 amino acid changes involved moderate to severe alteration of side
chain characteri tics and were thus likely to impact secondary and tertiary structures. In particular,
we found that mutations in nucleotide positions 269, 494, 749, n 763 cause amino acid ch nges
(resp ctively, positions 90, 165, 250, and 255) that are likely to trigger severe alt rations in the p otein
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chain. To predict whether these amino acid variations also affected protein function, we performed an
in silico functional analysis with PROVEAN. This analysis revealed that the mutation at the THCA
protein position 165 had a high probability to be deleterious (Figure 4A, in red). Based on this, it is
reasonable to assume that the catalytic activity of THCAS is low or null in fiber-type genotypes. On
the other hand, the translation of CBDAS indicated that the 4 bp deletion caused severe amino acid
changes (in detail, the deletion of Leu51 and Val52) that were predicted to be deleterious for the protein
function. Furthermore, a very early stop codon in position 583 of drug-type genotypes may cause a
truncated protein of 195 amino acids instead of 544. The PROVEAN analysis showed that the two
mutations at positions 136 (Arg/His) and 182 (Gly/Ala) were also deleterious (Figure 4B, in red). In all
these cases, the corresponding CBDAS truncated and/or mutated protein would make the enzyme
completely inactive.
4. Discussion
The aims of research on Cannabis varieties [1,34–36] have been mainly twofold: (i) to better
understand the biochemical mechanisms regulating the actual chemical profile of plants (thus
supporting both the toxic effects and the therapeutic applications) and (ii) to develop effective
tools suitable for forensic investigations in order to counteract the illegal market and provide
economic protection for the industrial cultivation of hemp. Despite efforts to establish genetic
relationships, as well as to highlight genetic differences among plant varieties (with different chemical
phenotypes and different psychoactive effects), these goals have remained challenging for the scientific
community to date, particularly concerning the two most investigated genes in cannabis, THCAS and
CBDAS. [13,19,23,24,37]).
Staginnus [16] developed a strategy to detect the BT/BT and BT/BD genotypes, independently
from the developmental stage of the plant and the tissues examined, confirming the two chemotype
classifications. In addition to the within-variety diversity observed by performing multidimensional
scaling of Gower distances, we found a simple and reliable way for discriminating between fiber-type
and drug-type samples.
Results emerging from this study showed significant genetic difference among two subgroups of
Cannabis in two genes regulating accumulation of THC in this plant species, allowing discriminating
between drug and fiber varieties. A first point of novelty in this work relates to the study of both
THCAS and CBDAS genes. In fact, considering that their derived proteins compete for the same
substrate, the involvement of both genes can provide a stronger and more robust discrimination
between drug and fiber varieties. Nonetheless, another point of novelty related to the identification of
18 amino acid substitutions in alignment of the sequences of high-THC and low/absent-THC accessions.
This information is essential to gain insights into the functionality of the enzyme. With this regard, four
amino acid substitutions appeared to induce a decrease in THCAS activity in the fiber-type cannabis
plants, and one of them was deleterious. Furthermore, the earlier stop codon at position 195 and the
4 bp deletion in the CBDAS sequence producing a frame-shift both cause a truncated protein and a
non-functional enzyme in high-THC accessions. Assuming that the protein encoded by THCAS could
still be active in fiber-type genotypes, the (shared) intermediate substrate cannabigerolic acid would be
preferentially metabolized by the high-affinity CBDAS-encoded enzyme. Drug-type genotypes possess
an opposite trend, having the CBDAS protein completely inactive and THCAS functional. In this
condition, the substrate cannabigerolic acid could be transformed by THCAS only despite its relatively
low affinity for the enzyme. Both these results were confirmed and validated at the metabolic level by
the chemical analysis of cannabinoids (Table 1).
Finally, highly reliable markers were identified, including the CBDAS deletion polymorphism
and the 33 identified SNPs (the eight loci in the CBDAS gene and 25 loci in the THCAS gene). We refer
to the associated score as (d). The score achieved an AUC of 100%, sensitivity of 100% (95% CI:
100.00–100.00%), and specificity of 100% (95% CI: 83.33–100.00%) at the zero threshold. A boxplot
of CBD and THC percentages is shown in Figure 5 (p < 0.001). These markers were not previously
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described by other authors such as Kojoma [10] and Rotherham-Harbison [15]. These markers are able
to distinguish between varieties prior to the stage of plant maturity (when the synthesis and storage of
cannabinoids begin). This will facilitate the early distinction of cannabis plants, as well as the selection
of cannabis seeds according to their applications in the primary sector (i.e., the cultivation of hemp for
textiles, cosmetics or the production of renewable energy) or pharmaceuticals (i.e., the production of
cannabinoids for therapeutic use), while at the same time providing an effective tool for controlling the
illicit drug market.
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maintains the lowest possible cost to expedite forensic investigations to suppress the illegal market
while also providing economic protection for the industrial cultivation of hemp.
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Author Contributions: All authors contributed to revise work critically for important intellectual content, gave
the final approval of the version to be published, and agreed on all aspects of the work especially concerning its
accuracy and integrity. Further specific activities have been distributed as follows: F.C. conceived the research
hypothesis and designed the study. L.B., I.B. and J.B. performed genetic analyses involving THCA synthase and
CBDA synthase gene sequencing and SNP identification. S.M., L.L., S.A. and D.M. performed chemical analyses of
Cannabis samples from experimental cultivations. A.F. and D.M. carried out bioinformatics and statistical analyses
of the d t and results from the experiments. F.C. J.B. wrote the manuscript with input from the team.
Plants 2019, 8, 496 11 of 12
Funding: The research conducted to obtain the results published herein was co-financed by the European
Commission Directorate General Justice through a grant of the project “Tracking Drug Trafficking”
JUST/2011/ISEC/DRUGS/AG/3670.
Acknowledgments: We thank G. Appendino, Università degli Studi del Piemonte Orientale, Italy, for kindly
providing the reference standards for cannabinoid analysis in hemp cultivars.
Conflicts of Interest: The authors declare that there are no competing financial interests. The European
Commission’s support for the production of this publication does not constitute endorsement of the contents,
which reflect the views only of the authors, and the Commission cannot be held responsible for any use that may
be made of the information contained herein.
References
1. ElSohly, M.A.; Slade, D. Chemical constituents of marijuana: The complex mixture of natural cannabinoids.
Life Sci. 2005, 78, 539–548. [CrossRef] [PubMed]
2. Hillig, K.W. Genetic evidence for speciation in Cannabis (Cannabaceae). Genet. Res. Crop. Evol. 2005, 52,
161–180. [CrossRef]
3. Fellermeier, M.; Zenk, M.H. Prenylation of olivetolate by a hemp transferase yields cannabigerolic acid, the
precursor of tetrahydrocannabinol. FEBS Lett. 1998, 427, 283–285. [CrossRef]
4. Fellermeier, M.; Eisenreich, W.; Bacher, A.; Zenk, M.H. Biosynthesis of cannabinoids. Incorporation
experiments with C13-labeled glucoses. Eur. J. Biochem. 2001, 268, 1596–1604. [CrossRef] [PubMed]
5. Raharjo, T.J.; Widjaja, I.; Roytrakul, S.; Verpoorte, R. Comparative proteomics of Cannabis sativa plant tissues.
J. Biomol. Tech. 2004, 15, 97–106. [PubMed]
6. Taura, F.; Morimoto, S.; Shoyama, Y.; Mechoulam, R. First direct evidence for the mechanism of
delta.1-tetrahydrocannabinolic acid biosynthesis. J. Am. Chem. Soc. 1995, 117, 9766–9767. [CrossRef]
7. Taura, F.; Morimoto, S.; Shoyama, Y. Purification and characterization of cannabidiolic-acid synthase from
Cannabis sativa L.: Biochemical analysis of a novel enzyme that catalyzes the oxidocyclization of cannabigerolic
acid to cannabidiolic acid. J. Biol. Chem. 1996, 271, 17411–17416. [CrossRef] [PubMed]
8. Thakur, G.A.; Duclos, R.I.; Makriyannis, A. Natural cannabinoids: Templates for drug discovery. Life Sci.
2005, 78, 454–466. [CrossRef] [PubMed]
9. Dussy, F.E.; Hamberg, C.; Luginbühl, M.; Schwerzmann, T.; Briellmann, T.A. Isolation of b9-THCA-A from
hemp and analytical aspects concerning the determination of n9-THC in cannabis products. Forensic Sci. Int.
2005, 149, 3–10. [CrossRef] [PubMed]
10. Kojoma, M.; Seki, H.; Yoshida, S.; Muranaka, T. DNA polymorphisms in the tetrahydrocannabinolic acid
(THCA) synthase gene in “drug-type” and “fiber-type” Cannabis sativa L. Forensic Sci. Int. 2006, 159, 132–140.
[CrossRef] [PubMed]
11. de Meijer, E.P.M.; Hammond, K.M.; Sutton, A. The inheritance of chemical phenotype in Cannabis sativa L.
(IV): Cannabinoid-free plants. Euphytica 2009, 168, 98–112. [CrossRef]
12. Pacifico, D.; Miselli, F.; Micheler, M.; Carboni, A.; Ranalli, P.; Mandolino, G. Genetics and marker-assisted
selection of the chemotype in Cannabis sativa L. Mol. Breed. 2006, 17, 257–268. [CrossRef]
13. Sirikantaramas, S.; Morimoto, S.; Shoyama, Y.; Ishikawa, Y.; Wada, Y.; Shoyama, Y.; Taura, F.
The gene controlling marijuana psychoactivity: Molecular cloning and heterologous expression of
1-tetrahydrocannabinolic acid synthase from Cannabis sativa L. J. Biol. Chem. 2004, 279, 39767–39774.
[CrossRef] [PubMed]
14. Yoshikai, K.; Taura, T.; Morimoto, S.; Shoyama, Y. DNA Encoding Cannabidiolate Synthase. Patent in Japan
JP 2000-78979A, 2001; DDBJ/EMBL/GenBank Database Accession Numbers E55107,
15. Rotherham, D.; Harbison, S.A. Differentiation of drug and non-drug Cannabis using a single nucleotide
polymorphism (SNP) assay. Forensic Sci. Int. 2010, 207, 193–197. [CrossRef] [PubMed]
16. Staginnus, C.; Zörntlein, S.; de Meijer, E. A PCR marker linked to a THCA synthase polymorphism is a
reliable tool to discriminate potentially THC-rich plants of Cannabis sativa L. J. Forensic Sci. 2014, 59, 919–926.
[CrossRef] [PubMed]
17. de Meijer, E.P.M.; Bagatta, M.; Carboni, A.; Crucitti, P.; Moliterni, V.M.C.; Ranalli, P.; Mandolino, G.
The inheritance of chemical phenotype in Cannabis sativa L. Genetics 2003, 163, 335–346. [PubMed]
18. van Bakel, H.; Stout, J.; Cote, A.; Tallon, C.; Sharpe, A.; Hughes, T.; Page, J.E. The draft genome and
transcriptome of Cannabis Sativa. Genome Biol. 2001, 12, R102. [CrossRef] [PubMed]
Plants 2019, 8, 496 12 of 12
19. Weiblen, G.D.; Wenger, J.P.; Craft, K.J.; ElSohly, M.A.; Mehmedic, Z.; Treiber, E.L.; Marks, M.D.
Gene duplication and divergence affecting drug content in Cannabis sativa. New Phytol. 2015, 208, 1241–1250.
[CrossRef] [PubMed]
20. Appendino, G.; Giana, A.; Gibbons, S.; Maffei, M.; Gnavi, G.; Grassi, G.; Sterner, O. A polar cannabinoid
from Cannabis sativa var. Carma. Nat. Prod. Commun. 2008, 3, 1977–1980. [CrossRef]
21. Calzolari, D.; Magagnini, G.; Lucini, L.; Grassi, G.; Appendino, G.B.; Amaducci, S. High added-value
compounds from Cannabis threshing residues. Ind. Crop. Prod. 2017, 108, 558–563. [CrossRef]
22. Gouy, M.; Guindon, S.; Gascuel, O. Seaview version 4: A multiplatform graphical user interface for sequence
alignment and phylogenetic tree building. Mol. Biol. Evol. 2010, 27, 221–224. [CrossRef] [PubMed]
23. Onofri, C.; de Meijer, E.P.M.; Mandolino, G. Sequence heterogeneity of cannabidiolic- and
tetrahydrocannabinolic acid-synthase in Cannabis sativa L. and its relationship with chemical phenotype.
Phytochemistry 2015, 116, 57–68. [CrossRef] [PubMed]
24. Taura, F.; Sirikantaramas, S.; Shoyama, Y.; Yoshikai, K.; Shoyama, Y.; Morimoto, S. Cannabidiolic-acid synthase,
the chemotype-determining enzyme in the fiber-type Cannabis Sativa. FEBS Lett. 2007, 581, 2929–2934.
[CrossRef] [PubMed]
25. Edgar, R.C. MUSCLE: Multiple sequence alignment with high accuracy and high throughput. Nucleic Acid Res.
2004, 32, 1792–1797. [CrossRef] [PubMed]
26. Tamura, K.; Stecher, G.; Peterson, D.; Filipski, A.; Kumar, S. MEGA6: Molecular evolutionary genetics
analysis version 6.0. Mol. Biol. Evol. 2013, 30, 2725–2729. [CrossRef] [PubMed]
27. Choi, Y.; Sims, G.E.; Murphy, S.; Miller, J.R.; Chan, A.P. Predicting the Functional Effect of Amino Acid
Substitutions and Indels. PLoS ONE 2012, 7, e46688. [CrossRef] [PubMed]
28. Firth, D. Bias reduction of maximum likelihood estimates. Biometrika 1993, 80, 27–38. [CrossRef]
29. Benjamini, Y.; Hochberg, Y. Controlling the false discovery rate: A practical and powerful approach to
multiple testing. J. R. Stat. Soc. Ser. B Stat. Methodol. 1995, 57, 289–300. [CrossRef]
30. Farcomeni, A. More powerful control of the false discovery rate under dependence. Stat. Methods Appl. 2006,
15, 43–73. [CrossRef]
31. Farcomeni, A. Some results on the control of the false discovery rate under dependence. Scand. J. Stat. 2007,
34, 275–297. [CrossRef]
32. Pepe, M.S. The Statistical Evaluation of Medical Tests for Classification and Prediction; Oxford University Press:
Oxford, UK, 2003.
33. Cox, T.F.; Cox, M.A.A. Multidimensional Scaling; Chapman and Hall: London, UK, 2001.
34. Cascini, F.; Aiello, C.; Di Tanna, G. Increasing delta-9-tetrahydrocannabinol (∆-9-THC) content in herbal
cannabis over time: Systematic review and meta-analysis. Curr. Drug Abus. Rev. 2012, 5, 32–40. [CrossRef]
35. Cascini, F.; Boschi, I. Tetrahydrocannabinol Concentration and Genetic Characterization of Cannabis.
In Handbook of Cannabis and Related Pathologies; Preedy, V.R., Ed.; Elsevier: London, UK, 2017.
36. Mehmedic, Z.; Chandra, S.; Slade, D.; Denham, H.; Foster, S.; Patel, A.S.; Ross, S.A.; Khan, I.A.; ElSohly, M.A.
Potency trends of n9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008.
J. Forensic Sci. 2010, 55, 1209–1217. [CrossRef] [PubMed]
37. Taura, F.; Tanaka, S.; Taguchi, C.; Fukamizu, T.; Tanaka, H.; Shoyama, Y.; Morimoto, S. Characterization of
olivetol synthase, a polyketide synthase putatively involved in cannabinoid biosynthetic pathway. FEBS Lett.
2009, 583, 2061–2066. [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
